Document is current
Any future updates will be listed below
-
Authors
Singer, Barry A. https://orcid.org/0000-0001-6875-7374
Wray, Sibyl
Gudesblatt, Mark https://orcid.org/0000-0002-3700-8554
Bumstead, Barbara
Ziemssen, Tjalf https://orcid.org/0000-0001-8799-8202
Bonnell, Ashley
Scaramozza, Matthew https://orcid.org/0000-0003-3738-459X
Levin, Seth
Shanmugasundaram, Mathura
Chen, Hailu
Mendoza, Jason P. https://orcid.org/0000-0003-2526-5542
Lewin, James B. https://orcid.org/0000-0002-2352-9113
Shankar, Sai L. https://orcid.org/0000-0003-3249-8360
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02634307 at ClinicalTrials.govDocuments that mention this clinical trial
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
https://doi.org/10.1007/s40120-024-00637-2
Diroximel fumarate pregnancy outcomes in EVOLVE-MS-1 and prospective MS pregnancy exposure registry study design
https://doi.org/10.1136/jnnp-2023-abn.206
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
https://doi.org/10.1007/s12325-022-02068-7
-
Funding
Funding for this research was provided by:
Biogen
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 30 May 2024
First Online: 27 June 2024
Declarations
:
: Barry A Singer: research grant support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis, and Sanofi; and consulting and/or speaking fees from AbbVie, Alexion, Biogen, Bristol Myers Squibb, Cigna, Cionic, EMD Serono, Genentech, Greenwich Biosciences, Horizon, Janssen, Novartis, Octave Bioscience, Roche, Sanofi, and TG Therapeutics. Sibyl Wray: consulting fees from and advisory boards for Biogen, Celgene, and EMD Serono; speaker bureaus for Biogen, Celgene, EMD Serono, Roche-Genentech, and Sanofi-Genzyme; research support from Biogen, Celgene, EMD Serono, Novartis, Receptos, Roche-Genentech, Sanofi-Genzyme, and TG Therapeutics. Mark Gudesblatt: speaker and consulting for Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi-Genzyme, Saol Therapeutics, and Teva Pharmaceuticals. Barbara Bumstead: speaker and consulting for Biogen, BMS, and Genzyme. Tjalf Ziemssen: personal compensation for consulting services and speaker honoraria from Biogen, BMS, Novartis, Roche, Sanofi, and Teva; and financial support for research activities from Biogen, Novartis, Roche, and Sanofi. Ashley Bonnell: speaker for EMD Serono; research support from Biogen, Celgene, EMD Serono, Novartis, Receptos, Roche-Genentech, Sanofi-Genzyme, and TG Therapeutics. Matthew Scaramozza, Seth Levin, Jason P Mendoza, Jim B Lewin, Sai L Shankar: employees of and hold stock/stock options in Biogen. Mathura Shanmugasundaram: was an employee of and may have held stock in Biogen at time of analysis. Currently an employee of Takeda. Hailu Chen: was an employee of and may have held stock in Biogen at time of analysis. Currently an employee of and holds stock/stock options in Alkermes.
: The study was conducted in accordance with protocol, the International Council for Harmonization Guideline E6, all applicable local regulatory requirements, and ethical principles based on the Declaration of Helsinki. Before enrollment of patients, the study protocol was reviewed and approved by the Copernicus Group institutional review board and the independent ethics committees for each study site. A list of these committees has been published previously []. All patients provided their written and informed consent ahead of participation in the study.
